<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Pormohammad A</submitter><funding>EC | European Regional Development Fund (ERDF)</funding><funding>Canadian Government | Natural Sciences and Engineering Research Council of Canada (NSERC)</funding><funding>EC | European Regional Development Fund</funding><funding>Canadian Government | Natural Sciences and Engineering Research Council of Canada</funding><pagination>e0007124</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11237694</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>12(6)</volume><pubmed_abstract>Novel antimicrobial agents are needed to combat antimicrobial resistance. This study tested novel pentafluorosulfanyl-containing triclocarban analogs for their potential antibacterial efficacy. Standard procedures were used to produce pentafluorosulfanyl-containing triclocarban analogs. Twenty new compounds were tested against seven Gram-positive and Gram-negative indicator strains as well as 10 clinical isolates for their antibacterial and antibiofilm activity. Mechanistic investigations focused on damage to cell membrane, oxidizing reduced thiols, iron-sulfur clusters, and oxidative stress to explain the compounds' activity. Safety profiles were assessed using cytotoxicity experiments in eukaryotic cell lines. Following screening, selected components had significantly better antibacteria</pubmed_abstract><journal>Microbiology spectrum</journal><pubmed_title>Novel pentafluorosulfanyl-containing triclocarban analogs selectively kill Gram-positive bacteria.</pubmed_title><pmcid>PMC11237694</pmcid><funding_grant_id>PID2021-122116OB-I00</funding_grant_id><funding_grant_id>Natural Sciences Engineering Research Council of Canada</funding_grant_id><funding_grant_id>Canada Research Chair</funding_grant_id><pubmed_authors>Vazquez S</pubmed_authors><pubmed_authors>Zarei M</pubmed_authors><pubmed_authors>Turner RJ</pubmed_authors><pubmed_authors>Pormohammad A</pubmed_authors><pubmed_authors>Pujol E</pubmed_authors><pubmed_authors>Naesens L</pubmed_authors><pubmed_authors>Hommes JW</pubmed_authors><pubmed_authors>Vazquez-Carrera M</pubmed_authors><pubmed_authors>Surewaard BGJ</pubmed_authors><pubmed_authors>Moradi M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Novel pentafluorosulfanyl-containing triclocarban analogs selectively kill Gram-positive bacteria.</name><description>Novel antimicrobial agents are needed to combat antimicrobial resistance. This study tested novel pentafluorosulfanyl-containing triclocarban analogs for their potential antibacterial efficacy. Standard procedures were used to produce pentafluorosulfanyl-containing triclocarban analogs. Twenty new compounds were tested against seven Gram-positive and Gram-negative indicator strains as well as 10 clinical isolates for their antibacterial and antibiofilm activity. Mechanistic investigations focused on damage to cell membrane, oxidizing reduced thiols, iron-sulfur clusters, and oxidative stress to explain the compounds' activity. Safety profiles were assessed using cytotoxicity experiments in eukaryotic cell lines. Following screening, selected components had significantly better antibacteria</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Jun</publication><modification>2025-04-19T20:07:31.11Z</modification><creation>2025-04-19T20:07:31.11Z</creation></dates><accession>S-EPMC11237694</accession><cross_references><pubmed>38700321</pubmed><doi>10.1128/spectrum.00071-24</doi></cross_references></HashMap>